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Many diseases with a genetic background such as some types of cancer are caused by damage in the p53
signaling pathway. The damage changes the system dynamics providing cancer cells with resistance to
therapy such as radiation therapy. The change can be observed as the difference in bifurcation diagrams
and equilibria type and location between normal and damaged cells, and summarized as the changes of
the mathematical model parameters and following changes of the eigenvalues of Jacobian matrix.
Therefore a change in other model parameters, such as mRNA degradation rates, may restore the proper
eigenvalues and by that proper system dynamics. From the biological point of view, the change of mRNA
degradation rate can be achieved by application of the small interfering RNA (siRNA). Here, we propose a
general mathematical framework based on the bifurcation theory and siRNA-based control signal in
order to study how to restore the proper response of cells with damaged p53 signaling pathway to
therapy by using ionizing radiation (IR) therapy as an example. We show the difference between the cells
with normal p53 signaling pathway and cells with abnormalities in the negative (as observed in SJSA-1
cell line) or positive (as observed in MCF-7 or PNT1a cell lines) feedback loop. Then we show how the
dynamics of these cells can be restored to normal cell dynamics by using selected siRNA.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Endogenous processes and exogenous agents can cause DNA
damage; for example, radiation can lead to double strand breaks
(DSB). Inefﬁcient DNA repair process or unrepairable DNA damage
induces genetical diseases, among them the most lethal one—
cancer. Maintaining genomic integrity is an important task of liv-
ing cells (Olivier et al., 2010). The p53 signaling pathway plays a
main role in this task by controlling genomic stability, thus, the
p53 protein is called ‘the guardian of the genome’. Its role is to
stop the cell cycle and initiate the DNA repair process after theLtd. This is an open access article u
Kozłowska),DNA damage detection. If the cell is unable to maintain genome
integrity, the p53 signaling pathway triggers apoptosis (Zilfou and
Lowe, 2009) or senescence (Lindgren et al., 2015). From the mo-
lecular point of view, the core of p53 signaling pathway functions
as follows: in normal cells the p53 level is kept low by its inhibitor
Mdm2, which is transcriptionally dependent on p53. It deﬁnes
negative feedback loop. On the other hand, p53 regulates PTEN
transcription, which through PIP3 and Akt blocks the Mdm2
phosphorylation which is necessary for its nuclear entry and p53
inhibition. This deﬁnes the positive feedback loop. DNA damage
results in p53 phosphorylation which protects p53 from Mdm2
(p53 inhibitor) and simultaneously enhances Mdm2 degradation
(Puszynski et al., 2008). The p53 protein concentration increases.
When the p53 concentration crosses the ﬁrst threshold deﬁned by
Kracikova et al. (2013), the cell cycle is arrested to prevent trans-
mission of the damage to daughter cells. Unsuccessful DNA repairnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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causes Mdm2 blockade in the cytoplasm and further increase of
the nuclear p53 level. Finally, when p53 level crosses the second
threshold, apoptosis or senescence is initiated.
The mechanism of maintaining genome integrity is, however,
disabled in many cancers through mutations of the p53 protein
itself or abnormalities in the p53 signaling pathway (Muller and
Vousden, 2013). Such alterations can be observed for example in
many sarcomas. Strong Mdm2 over-expression caused e.g. by
strong Mdm2 gene ampliﬁcation up to 25 in SJSA-1 cells (Tovar
et al., 2006) leads to very strong p53 inhibition and its inability to
cross even the ﬁrst threshold. This could be the reason of the
sarcomas resistance to ionization radiation therapy. Another
malfunction of mechanisms to protect cells genome integrity is
observed in the MCF-7 cells (breast cancer) where PTEN gene
methylation (Krawczyk et al., 2007) disables the positive feedback
loop. PTEN loss was observed also in the PNT1a cells (prostate
cancer) (Mak et al., 2012) and some of the subtypes of diffuse large
B-cell lymphoma (DLBCL) (Pfeifer et al., 2013). Consequently, in-
creased p53 level is followed by the Mdm2 production and p53
degradation. Hence, in these cells we observe sustained p53-
Mdm2 level oscillations below the apoptotic/senescence threshold
level.
Radiation and other classical treatments of patients with cancer
cause signiﬁcant apoptotic death or senescence of tumor cells, as
well as damage to surrounding healthy tissues. Hence, the treat-
ments may induce serious morbidity and potentially fatal out-
comes. What is more, one hallmark of tumor cells is resisting
programmed cell death (Hanahan and Weinberg, 2011). It means
that tumor cells are prone to escaping from apoptosis or senes-
cence e.g. by the mechanisms described above. Therefore, a me-
chanism which sensitizes tumor cells to radiation is of great in-
terest. Despite the technological advances in the ﬁeld of radiation
oncology, overcoming tumor cells' radio-resistance remains a
therapeutic challenge (Ding et al., 2013).
Sensitization of cancer cells to irradiation could be achieved by
introduction of some artiﬁcial molecules such as those based on
interfering RNA (Davis, 2009) or chemical compounds (Vassilev
et al., 2004). From these possibilities, the RNA interference (RNAi)
based silencing mechanism is the most reliable method, because it
additionally allows avoiding severe side effects which often ac-
company such methods. These features attracted the attention of
researchers in many ﬁelds ranging from basic science studies to
clinical medicine, aiming to provide new insights into the methods
of treatment and cancer prevention, viral infections and auto-
immune disorders (Dorsett and Tuschl, 2004; Hannon and Rossi,
2006; Ryther et al., 2005).
RNA interference (RNAi) is a process of sequence-speciﬁc gene
silencing discovered by Andrew Fire and colleagues in 1998 (Fire
et al., 1998). They observed that the introduction of external
double-stranded RNAs can initiate sequence-speciﬁc degradation
of mRNAs which are homological to the dsRNA. RNAi governs key
resistance mechanisms in cells to endogenous and exogenous
nucleic acids, as well as regulates gene expression. With increasing
progress in understanding the molecular mechanisms of the RNAi
pathway and discovery of miRNA and siRNA (effector molecules of
the RNA interference), the phenomenon has been applied in var-
ious areas: nanomedicine (Tokatlian and Segura, 2010), functional
genomics (Kiger et al., 2004) and cancer biology (Fuchs and Bor-
khardt, 2007).
In contrast to miRNA, siRNA do not naturally exist in human
cells and have higher speciﬁcity and the ability to almost entirely
silence the expression of a single target gene. It makes them
especially useful as a controlling agent in therapeutic studies(Bumcrot et al., 2006). The biggest disadvantage of the siRNA
compared to miRNA is the fact that only negative regulation is
available through the direct inﬂuence of siRNA. Positive regulation
is only achievable indirectly through double negation, such as the
blockage of target gene repressor. In case of the miRNA, gene si-
lencing is related to over-expression of miRNA, and over-expres-
sion of target mRNA is caused by knockdown of miRNA.
Another problem arises in the in vivo research. The efﬁciency of
the iRNA transport into the cell is one of the most crucial elements
in efﬁciency of siRNA or miRNA based therapy. siRNA/miRNA can
be introduced to the cells in their mature form directly or with the
help of transporting agents such as polymer-based nanoparticles.
Kim et al. (2004) reported high efﬁciency of local and systematic
delivery of naked siRNA in animal models. What is more, Shim and
Kwon (2010) proved that targeting agents can signiﬁcantly in-
crease siRNA's effectiveness. Another group of methods involve
transfection of small RNA-expressing constructs with the help of
viral or plasmid vectors, which results in their intercellular pro-
duction with long term effect (Makinen et al., 2006).
Besides the biological discoveries, another effort to better un-
derstand cancer and determine possible treatment is taken by
system biologists. Through the mathematical model development
and its analysis, they try to understand how the biological pro-
cesses are governed by signal transduction pathways, and explain
the complex interactions between the proteins, mRNAs, siRNAs or
miRNAs, and the dynamics of such interactions (Bartlett and Davis,
2006; Groenenboom and Hogeweg, 2008; Puszynski et al., 2012).
Systems biology is not only able to integrate information from
multiple sources into a coherent quantitative model, but also
through computational and mathematical methods such as bi-
furcation and sensitivity analysis to provide the key information
useful for therapy planning and drug development; Young and
Michelson, 2011). For example, bifurcation analysis could provide
information concerning the differences between the dynamics of
intracellular processes in normal and cancer cells, and sensitivity
analysis can reveal the key points in the signaling pathway which
would be the best targets for therapy development. For example,
mathematical description of small RNA has proven its usefulness
providing precious pharmacodynamics simulation data used in
various clinical trials including the design of CALAA-01 dosage
system, successfully tested on patients with solid tumors in a
phase I clinical trial (Davis et al., 2010).
The term Bifurcation was introduced by Henri Poincare in 1885
(Poincare, 1885). Bifurcation in the system occurs when small
change of one or more of its parameters causes qualitative change
in the system's behavior, such as destabilization, oscillations born
or chaos initiation. From the mathematical point of view, such a
change is related to the change of equilibrium point type of our
system or equilibria position change and their collision which can
be observed as change in the eigenvalues of Jacobian matrix of the
examined model. The parameter which causes system behavior
change is called bifurcation parameter, and the value of that
parameter at which the change occurs is named bifurcation point.
Examining bifurcation diagrams has contributed toward un-
derstanding of how observed biological response arises out of
signaling pathway topology and parameters. Bifurcation theory
(see Kuznetsov, 2004 for overall introduction) has two main ap-
plications in biology (Lu et al., 2006). The ﬁrst one is to locate
regions in parameter space exhibiting biologically meaningful bi-
furcation type behavior by mapping parameter space to the bi-
furcation diagram. It is called forward problem and is useful for
understanding which possible behaviors may arise out of the given
mathematical model. For instance, Tyson et al. performed bi-
furcation analysis to explain dynamics of growth and reproduction
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unravel causes for observed or desired effects by mapping bi-
furcation diagram to parameter space (inverse problem). It can be
used to explain in the form of biochemical parameters how model
dynamics arise. For instance, Lu et al. (2006) applied inverse bi-
furcation analysis of check points in mammalian cell phase
transition.
Our previous results (Puszynski et al., 2012) show possibilities
of p53 pathway regulation by siRNA. We demonstrated that si-
lencing Mdm2 by siRNA can increase sensitivity to irradiation of
tumor cells with aberrations in the p53 pathway. Based on a si-
mulation study we established that problems of radiotherapy
dosage limitations can be avoided by using a siRNA based control
mechanism. Here, we extended the studies by proposing a general
mathematical framework, based on bifurcation theory, to de-
termine model parameters which have to be changed by siRNA
application and the value of this change in order to restore proper
cell functioning. Additionally, we wanted to explore the possibility
of immunization of the healthy cell to ionization radiation. The
idea was to imitate the cancer-speciﬁc immunization which, as
mentioned, is through the Mdm2 over-expression or PTEN silen-
cing. Since we wanted to use siRNA as the input we chose to use
PTEN targeted siRNA to reduce its expression. SiRNA inputs can
signiﬁcantly improve IR based therapy or other therapies based on
DNA damage induction by sensitization of the cancer cells with
simultaneous immunization of the healthy ones. It should lower IR
or other damaging agent doses and decrease of the side effects.Fig. 1. Model scheme. Ellipses stands for model variables, solid lines for transitions whil
phosphorylationwhile circle with “u”means ubiquitination. Please notice the model inpu
positive feedback loop p53-PTEN-PIP3-Akt-PTEN-Mdm2.2. Materials and methods
The aim of our work was to investigate the possibility of sen-
sitization of the cancer cells and immunization of the healthy ones
to the IR by using siRNA targeted for Mdm2 and PTEN mRNA re-
spectively. To test it, we developed a mathematical model which is
modiﬁcation of our newest p53 signaling pathway model pre-
sented in Puszynski et al. (2014). The modiﬁcation includes re-
moval of the Nutlin control signal and addition of the IR and siRNA
inﬂuence on the system (see Fig. 1). The whole model is described
in detail in the Supplementary Materials. Here we describe only
the equations crucial for our research. Eqs. (1) and (2) describe
Mdm2 and PTEN genes state change in time. The ﬁrst term stands
for p53 independent and dependent gene activation while the
second for spontaneous gene deactivation. Power 2 in the ﬁrst
term reﬂects the fact that main transcription factor role is played
by p53 tetramers while normally it is present in cell as a dimer.
Parameters nMDM and nPTEN state for the Mdm2 and PTEN func-
tional gene number. In normal cells we have two functional copies
of each gene so = =n n 2MDM PTEN .
In many cancers Mdm2 over-expression is related to Mdm2
gene ampliﬁcation caused by the chromosome mutation. Usually
ampliﬁcation ranges between 2- and 10-fold (Momand et al., 1998)
(up to 25 in SJSA-1 cell line, Tovar et al., 2006). To imitate cancer
cells with Mdm2 gene ampliﬁcation we set =n 4MDM .
The second type considered was breast (MCF-7 cell line) or
prostate (PNT1a cell line) cancer with characteristic PTEN gene
blockade. To imitate this we set =n 0PTENe dashed for inﬂuences. Crossed circle symbolize degradation, circle with “P” means
ts: IR and external siRNA (Mdm2 and PTEN); negative feedback loop p53-Mdm2 and
Fig. 2. Bifurcation diagram of the presented model. For the IR dose <1.9 Gy we
have only one equilibrium point with low dose of p53 which we call “proliferation”
equilibrium. For the IR dose >3.2 Gy we also have one equilibrium point but with
high p53 level which is called “apoptotic”. Between these two regions we have
region of bistability where both solution exist and thus depending on the initial
conditions and/or stochastic processes realization (in stochastic case) cells could
choose proliferation or apoptosis.
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Eqs. (3) and (4) describe MDM2 and PTEN mRNAs amount
changes in time. The ﬁrst term stands for mRNA production which
depends on the number of active genes, the second term stands
for spontaneous and the third for siRNA dependent mRNA de-
gradation. Saturation term in these equations reﬂects the known
biological fact that mRNA silencing caused by siRNA cannot reach
100%. In fact we were able to reach 90% maximum in our wet-lab
(data not shown).
( ) = ( ) − ( ) −
+
( ) ( )
d
dt
MDM t s G t d MDM t sd
SIRMDM
SIRMDM sh
MDM t . 3
RNA MDM RNA
RNA
0 6 1
1
( ) = ( ) − ( ) −
+
( ) ( )
d
dt
PTEN t s G t d PTEN t sd
SIRPTEN
SIRPTEN sh
PTEN t . 4
RNA PTEN RNA
RNA
1 7 2
2
Model simulations and analysis were performed in Matlab
environment.3. Results
We performed the analysis of our model for the “normal” cells,
which means the cells with properly functioning p53 module such
as RKO cells, then cells with ampliﬁcation in the negative feedback
loop such as SJSA-1 cells and in the last case the cells with mal-
function of the positive feedback loop such as MCF-7 or PNT1a
cells. The difference between these cell types is the number of
Mdm2 or PTEN alleles. Normal cells have two copies of both
Mdm2 and PTEN alleles. Cells with ampliﬁcation in the negative
feedback loop have four copies of Mdm2 and two copies of PTEN
allele while cells with not-functional positive feedback loop have
two copies of Mdm2 and 0 copies of PTEN alleles (see Table 1).
The bifurcation diagram of the cells with fully functioning p53
pathway reveals three regions of the system response to the var-
ious dose of IR (see Fig. 2). In the ﬁrst region, low dose of IR
(< )1.9 Gy causes small number of DSBs which are rapidly repaired.
As a result, all cells in population repair their DNA so they go to
“proliferation” equilibrium point in which we have low level of
p53. In the second region ( < < )1.9 IR 3.2 Gy , we have two equi-
libria: “proliferation” and “apoptosis”. Because of the heterogeneity
and stochasticity of the intracellular processes such as gene acti-
vation/deactivation the cells population will split on two sub-
populations. Some cells will be able to repair their DNA and go toTable 1
Parameter values for three different model types: “normal”, with ampliﬁcation in
negative feedback loop and damaged positive feedback loop. Rest of the parameters
as well as model equations are presented in supporting materials.
Cell type No. MDM2 alleles No. PTEN alleles
“Normal” cells 2 2
Cells with ampliﬁed negative feedback
loop
4 2
Cells with damaged positive feedback
loop
2 0the “proliferation” equilibrium while others will not and chose
“apoptotic” equilibrium. For large enough IR ( > )3.2 Gy the DNA
damage caused is so extensive that all cells in population die.
This is also visible on the p53-Mdm2nuc phase plane (Fig. 3
upper row). As expected the abnormalities of the feedback loops
typical for cancers have impact on the cells behavior and thus their
bifurcation and phase-plane diagrams. For all cells type for the
IR¼1 Gy, as expected, we have only one stable equilibrium point
(Fig. 3 column A) with low amount of p53 so it is “proliferation”
equilibrium. For the IR¼2 Gy the “normal” cells exhibit two stable
equilibria one “proliferation” with low level of p53 and second
“apoptotic” with high level of p53, while for IR¼5 Gy we can ob-
serve only one “apoptotic” equilibrium point with high level of p53
(Fig. 3 ﬁrst row, columns B and C). Ampliﬁcation in the negative
feedback loop causes bifurcation point to shift from 1.9 Gy to
21 Gy, so the doses of 2 and 5 Gy are not enough to cause apop-
tosis and only one “proliferation” equilibrium exists for these cells
(Fig. 3 second row, columns B and C). Similar effect can be ob-
served in cells with inactive positive feedback loop although the
reason behind is different. In these cells, because of the positive
feedback loop malfunction, the negative feedback cannot be
switched off and thus the “apoptotic” solution does not exist even
for extensive DNA damage (Fig. 3 last row, columns B and C).
In both considered cancer types the p53 signaling pathway
malfunction results in the elevated nuclear Mdm2 level and thus
low p53 level in time when the apoptotic decision has to be made.
To overcome this malfunction we propose to use Mdm2 targeted
siRNA. Our goal was to restore the proper cell response to the DNA
damage, which may be considered as the restoration of the
“apoptotic” equilibrium point type and location. We used bifurca-
tion analysis in the iterative way to determine the optimal siRNA
dosage for both malfunction type cells (Fig. 4). We found that
“apoptotic” equilibrium point location and type will be the same as
in “normal” cells when we tread cells with ampliﬁcation in nega-
tive feedback with dose of 5.2 nM of Mdm2 targeted siRNA while
cells with malfunction in positive feedback with dose 4.2 nM
(Fig. 4 left and right panels respectively).
As expected, introduction of the optimal siRNA doses to the
Fig. 3. p53-Mdm2 phase plane for different doses of IR and cell types in case without siRNA treatment. Black dots present equilibrium points location while grey lines sample
trajectories. Column A: IR dose 1 Gy, column B: IR dose 2 Gy, column C: IR dose 5 Gy. Normal cells (ﬁrst row) have one “proliferation” equilibrium point for IR dose 1 Gy, one
“apoptotic” for IR dose 5 Gy and both of them for dose 2 Gy. Cancer cells with malfunction in negative (second row) or positive (third row) feedback loop have only
“proliferation” equilibrium and thus are unable to die due apoptosis.
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Fig. 4. Determination of the optimal siRNA dose to restore proper response of the cells with malfunction in feedback loop. Dashed lines represent the location of the
“apoptotic” equilibrium point in normal cells irradiated with dose 5 Gy. Solid lines represent the location of the equilibrium in cells with ampliﬁcation in the negative
feedback loop (left panel) and cells with damaged positive feedback loop (right panel).
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to DNA damage (Fig. 5). All cell types respond in the same, correct
way to the various doses of IR. 1 Gy of IR results in the existence of
one “proliferation point” (Fig. 5 column A). With 2 Gy we have
“proliferation” and “apoptotic” equilibria (Fig. 5 column B) while for
high dose of 5 Gy only “apoptotic” equilibrium point exist. (Fig. 5
column A).
One of the major disadvantages of the IR based therapy are the
side effects caused by the radiation taken by the healthy cells. The
technical limitations do not allow to deliver the radiation only to
the cancer cells, usually it has to travel through the healthy cells
before it reaches tumor. Hence, it could be useful to immunize the
healthy cells to radiation and thus limit the side effects. As we
showed before the cells can be immunized to IR e.g. by ampliﬁ-
cation in the negative feedback loop or by switch off of the positive
feedback of the p53 signaling pathway. Therapeutic extortion of
the negative feedback ampliﬁcation can be challenging or even
impossible while silencing of the positive feedback is possible
through proper siRNA. Complete silence of the selected gene by
siRNA is usually impossible but with proper dose we can silence it
to around 10% (Puszynski et al., 2012). To explore the possibility of
“normal” cell immunization to IR we checked how the bifurcation
points location depends on the siRNA dose (Fig. 6). One can notice
strong dependence between them. The higher siRNA dose the
higher IR and thus more extensive DNA damage is required to
push the cells to apoptosis.4. Discussion
In our work we present that “normal” cells can choose between
two possible stable equilibrium points: proliferation or apoptosis.
In case of low or medium DNA damage level, these equilibria are
reached by the damped oscillations manner. When DNA damage is
too high cells quickly die and no oscillations are observed. This
damped oscillations behavior reproduced in our model may be
due the dominant role of PTEN feedback which, with sufﬁcient
time, push cells to the apoptotic solution, or more likely due to
deterministic approach (required by bifurcation analysis), while
stochastic model reproduce sustained oscillations (see Liu et al.,
for more details). In some papers, authors reported sustained os-
cillations of p53 and Mdm2 levels after DNA damage. Such beha-
vior was observed for in vitro cells by Uri Alon group(Geva-Zatorsky et al., 2006) and Lahav group (Batchelor et al.,
Chen et al., 2016) and for in vivo cells by Hamstra et al. (2006).
Presence of the sustained or damped oscillations may depend on
the studied cell type, so the model adjustments (e.g. lowering the
strength of PTEN inﬂuence) may be required each time particular
cells type is considered. In the case of sustained oscillations, in-
stead of trajectories aiming at the equilibrium points, we could
observe trajectories orbiting equilibrium points. However, ex-
istence and location of these equilibrium points still could be de-
termined and changed by the siRNA administration.
Please notice that our siRNA dosage was based on the in-
formation provided by commercial siRNA manufacturers that the
siRNA concentration of 30 nM outside the cell results in 75% si-
lencing efﬁciency. When the siRNA sets of different efﬁciency are
used, the parameters responsible for mRNA degradation by siRNA
in the model need to be adjusted.5. Summary and conclusions
In this work, we presented a general mathematical framework
based on the bifurcation theory that allows to:
 visualize the differences in the dynamics of various types of
cells (for example cells with normal and damaged p53 signaling
pathway),
 determine the difference in equilibrium points and their loca-
tion between various cells,
 determine the parameters which have to be changed to restore
proper bifurcation diagrams and equilibria type and location,
 determine of the dose of additional control signals, such as
siRNA, whose role is to provide the necessary changes in the
model parameters e.g. change of the mRNA degradation rate.
Although in the paper we often refer to IR as input signal in fact
the only impact of IR we consider is to cause DNA damage which
activates the p53 pathway. Therefore our results should be correct
also for other agents as long as only the DNA damage is
considered.
In some cells, such as MCF-7, because of other than the p53-
core damage, even the restoration of the proper p53-core func-
tioning may not be enough to cause p53-dependent apoptosis.
However, in these cells elevated p53 level can cause their
Fig. 5. p53-Mdm2 phase plane for different doses of IR and cell types in case with siRNA treatment. Black dots present equilibrium points location while grey lines sample
trajectories. Column A: IR dose 1 Gy, column B: IR dose 2 Gy, column C: IR dose 5 Gy. As one can notice proper dosage of siRNA restored the type and location of the
“apoptotic” equilibrium point in the cells with ampliﬁcation in negative feedback (second row) or damaged positive feedback (third row) to the type and location of the
equilibrium in normal cells (ﬁrst row).
E. Kozłowska, K. Puszynski / Journal of Theoretical Biology 408 (2016) 213–221 219
Fig. 6. Bifurcation plot for cells with normally functioning p53 pathway as a
function of irradiation and PTEN targeted siRNA. One can notice that the higher
dose of siRNA targeted to PTEN the higher IR dose is required to switch the cells
from low p53 region (proliferation) to high p53 region (apoptosis). This proves that
PTEN targeted siRNA can immunize cells to IR.
E. Kozłowska, K. Puszynski / Journal of Theoretical Biology 408 (2016) 213–221220senescence, i.e. permanent cell cycle arrest, which also blocks the
cancer development and may be considered as a therapy goal.
One has to remember that the purpose of this article was not
the comprehensive modeling of the p53 signaling pathway but
presentation of the methodology based on bifurcation analysis and
siRNA application.
We used p53 the signaling pathway as an example because its
structure is well known and the parameters are determined for
many cell lines. The model parameters are gained from the in vitro
experiments and the siRNA inﬂuence on the cells is also con-
sidered as in the in vitro experiments, e.g., we assumed a constant
siRNA concentration outside the cells.
The real application of our approach in patient treatment re-
quires a few additional modiﬁcations. First of all, the model
parameters should be taken from the patient's cells. It can be done
through the biopsy of the cancer and healthy surrounding tissue. It
will allow to determine the difference between the healthy and
cancer cells from the system dynamics point of view. Then, the
best target for siRNA based therapy should be determined. If there
is more than one possible target, sensitivity analysis can be applied
to provide parameter ranking where the higher place means better
therapy target (Puszynski et al., 2012).
Another major problem with the in vivo application of our
method is the delivery system. Oral and intravenous administra-
tion of the drug usually leads to its presence in all body tissues.
This can lead to serious side effects, which can lead to more harm
from the therapy than beneﬁts. Therefore, it could be useful to
provide a targeted delivery system, such as proposed by Davis
(2009) or by Shim and Kwon (2010). Considering in vivo applica-
tion of our approach, it is also necessary to model the delivery
system and the pharmacokinetics of the siRNA. It can be done by
using the time plots of the siRNA concentration in the tissues as
we did in Puszynski et al. (2014). As shown in Puszynski et al.
(2016), also the stochasticity of gene switching cannot be ne-
glected when pharmacodynamics of the drug such as siRNA is
considered.
Our approach can be used also for the sensitization to IR of the
cells with properly functioning p53 pathway. It will allow to lower
the IR dose and side effect or receive the higher apoptotic fraction
of the cancer cells while keeping the IR dose. On that way theproblem of radiotherapy dosage limitations can be avoided.
With the growing number of the publications discovering
various signaling pathways structure and parameters, and by
growing power of the computational systems and improvements
in the targeted delivery systems, it becomes possible to provide
truly personalized therapy. In this system, bifurcation theory can
provide the information on the target and dose, while siRNA can
be used as one of the controlling signal.Acknowledgments
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